Shots:
- The US FDA has approved AptimaHPV Assay, an mRNA-based assay for clinician-collected HPV primary screening
- Approval follows completion of a real-world HPV screening study of 650,000+ women across US, showing the Aptima HPV Assay has clinically comparable sensitivity to an FDA-approved DNA-based HPV test & is effective for detecting CIN2+ & CIN3+ in primary screening
- The Aptima HPV Assay now supports all three FDA-approved, guideline-recommended cervical cancer screening options (Pap testing, HPV primary testing, & Pap + HPV co-testing), strengthening its comprehensive screening portfolio
Ref: Businesswire | Image: Hologic | Press Release
Related News: Blackstone and TPG Acquire Hologic for ~ $18.3B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
